Document:

EX-10.3

 Exhibit 10.3 

CASTLE CREEK BIOSCIENCES, INC. 

STOCK OPTION AGREEMENT 

Castle Creek Biosciences, Inc., a Delaware corporation (the “Company”), is pleased to advise you, the
“Participant” whose signature appears on the signature page hereto, that the Company has granted to you a stock option (an “Option”), as provided below, under the Company’s Amended and Restated Management
Incentive Plan (as amended from time to time, the “Plan”), a copy of which is attached hereto and incorporated herein by reference. The Option has been granted, and the shares of Common Stock issuable upon exercise will be issued,
pursuant to a “compensatory benefit plan” within the meaning of such term under Rule 701 of the Exchange Act. 
  

					
	      	 	Participant Name:	  	                                      
               
			
		 	Address:	  	On file with the Company            

 You have been granted an Option to purchase shares of Common Stock of the Company, subject to the terms and
conditions of the Plan and this Stock Option Agreement, as follows: 
  

							
		 	Date of Grant:	  	                                    
                                
			
	      	 	Commencement Date:	  	                                    
                                
			
		 	Exercise Price per Share:	  	  $                                  
                              
			
		 	Total Number of Shares subject to Option:	  	                                    
                                
			
		 	Total Exercise Price:	  	  $                                  
                              
				
		 	Type of Option:	  	       	 	Incentive Stock Option
				
		 		  	  X  	 	Nonstatutory Stock Option
			
		 	Expiration Date:	  	                                    
                                

 1. Definitions. Capitalized terms used but not defined in this Stock Option Agreement
(this “Agreement”) shall have the meanings set forth in the Plan. 
 2. Option. 

(a) Grant. This Option entitles you to purchase up to the number of shares of Common Stock set forth on the first page of this Agreement
at an exercise price per share (the “Exercise Price”) as set forth on the first page of this Agreement. Your Option shall expire at the close of business on the expiration date set forth on the first page of this Agreement (the
“Expiration Date”), subject to earlier expiration as provided in Section 3 below. Your Option is not intended to be an “incentive stock option” within the meaning of Section 422 of the Code.

 (b) Payment of Option Price. Subject to Section 3 below, your Option may be exercised in whole or in part
upon payment of an amount (the “Option Price”) equal to the product of (i) the Exercise Price multiplied by (ii) the number of shares of Common Stock to be acquired, unless otherwise determined by the
Committee. Payment of the Exercise Price shall be by any of the following, or a combination of the following, at your election: (A) cash or check; (B) at the discretion of the Committee on a case by case basis, by surrender of other shares
of Common Stock of the Company that have an aggregate Fair Market Value on the date of surrender equal to the aggregate Exercise Price of the shares as to which this Option is being exercised; or (C) at the discretion of the Committee on a case
by case basis, by a cashless exercise or promissory note program approved by the Committee. 
 3. Vesting; Expiration; Exercisability.

 (a) Vesting. Your Option may be exercised only to the extent it has become vested. Subject to your continued employment or
engagement by the Company or another member of the Company Group (as defined on Exhibit B attached hereto) on each applicable vesting date, and except as may otherwise be provided herein or in the Plan, twenty percent (20%) of the Option
shall become vested on the first anniversary of the Commencement Date (the “First Vesting Date”), and the remaining eighty percent (80%) shall become vested ratably on each of the subsequent four anniversaries following the First
Vesting Date. The Option shall not vest at any time after the termination of your employment or engagement with the Company. 
 (b) Change
in Control. Notwithstanding anything to the contrary herein, upon the occurrence of a Change in Control, and irrespective of whether outstanding Options are being assumed, substituted, exchanged or terminated in connection with the transaction,
the vesting of your Option shall accelerate such that all unvested Options shall become exercisable and vested to the extent not then otherwise vested. The portion of your Option that has not yet become vested shall become vested as provided herein
due to a Change in Control if and only if, as of the date of the consummation of such Change in Control, you remain employed or engaged by the Company or another member of the Company Group from the Commencement Date through and including
such Change in Control. In any event, any portion of your Option which has not been exercised prior to or in connection with the Change in Control shall expire and be forfeited for no consideration, unless otherwise determined by the Committee. 

(c) Expiration of Option. In no event shall any part of your Option be exercisable after the Expiration Date. 

  
 2 

 (d) Early Expiration upon Termination of Employment. Any portion of your Option that
was not vested and exercisable as of the date on which your employment or service with the Company or another member of the Company Group terminates shall expire and be forfeited on such date. Any portion of your Option that was vested and
exercisable as of such termination date shall also expire and be forfeited as of such termination date, provided, however, (i) if such termination was by reason of Participant’s death or Disability (as defined in the Plan), then the
portion of your Option that was vested and exercisable as of such termination date shall remain exercisable until the earlier of (w) one hundred twenty (120) days following the effective date of such termination and (x) the expiry of
the Option on the Expiration Date; and (ii) if such termination was by the Company without Cause (as defined in the Plan), and the Participant has executed and delivered to the Company a general release of claims against the Company and the
Company Group, in form and substance acceptable to the Committee, and such release has become irrevocable, then the portion of your Option that was vested and exercisable as of such termination date shall remain exercisable until the earlier of
(y) sixty (60) days following the effective date of such termination and (z) the expiry of the Option on the Expiration Date; 

(e) Procedure for Exercise. You may exercise all or any portion of your Option, to the extent it has vested and is exercisable, at any
time and from time to time prior to its expiration, by delivering to the Company’s Corporate Secretary an Exercise Notice in the form attached to this Option, and a duly executed joinder, in form and content acceptable to the Company, to all or
portions of any stockholders, financing, or other agreement as determined by the Committee, together with payment of the Option Price in accordance with the provisions of Section 2(b) above. As a condition to any exercise
of your Option, you shall make all customary investment representations which the Company requires. The Company is not obligated, and will have no liability for failure, to issue or deliver any shares of Common Stock upon exercise of this Option
unless such issuance or delivery would comply with applicable laws, with such compliance determined by the Company in consultation with its legal counsel. As a condition to the exercise of your Option, and as further set forth in Section 7 of
this Agreement, you agree to make adequate provision, acceptable to the Company, for federal, state, local and non-U.S. income an employment tax withholding obligations, if any, which arise upon the grant,
vesting or exercise of this Option, or disposition of shares of Common Stock acquired upon exercise of this Option, whether by withholding, direct payment to the Company, or otherwise. Further, if you (or any other person) is exercising this Option
in connection with or following the termination of your employment or engagement with the Company or another member of the Company Group, as a condition to exercise of your Option and the issuance of shares of Common Stock hereunder, you shall
execute and deliver to the Company a general release of claims with respect to the termination of your employment or engagement with the Company or another member of the Company Group in form and substance provided to you by the Company at that
time. 
 4. Conformity with Plan. Your Option is intended to conform in all respects with, and is subject to all applicable provisions
of, the Plan (which is incorporated herein by reference). Inconsistencies between this Option and the Plan shall be resolved in accordance with the terms of the Plan. By executing and returning the enclosed copy of this Option, you acknowledge your
receipt of this Option and the Plan and agree to be bound by all of the terms of this Option and the Plan. 
 5. Rights of
Participants. Nothing in this Option shall interfere with or limit in any way the right of the Company or any member of the Company Group to terminate your employment or engagement at any time (with or without Cause), nor confer upon you any
right to continue to be employed or engaged by the Company or another member of the Company Group for any period of time or to continue your present (or any other) rate of compensation or benefits. In the event of any termination of your employment
or engagement with the Company or another member of the Company Group (including any termination of your employment or engagement by the Company or another member of the Company Group without Cause), any portion of your Option that was not
previously vested and exercisable shall expire and be forfeited, except as otherwise provided herein or in the Plan. Nothing in this Option shall confer upon you any right to be selected again as a participant under the Plan, and nothing in the Plan
or this Option shall provide for any adjustment to the number of shares of 

  
 3 

 
Common Stock subject to your Option upon the occurrence of subsequent events, except as provided in Section 7 or the Plan. Also, to the extent applicable, the Exercise Price has been set in
good faith compliance with the applicable guidance issued by the IRS under Section 409A of the Internal Revenue Code of 1986, as amended. However, there is no guarantee that the IRS will agree with the valuation, and by signing below, you agree
and acknowledge that the Company shall not be held liable for any applicable costs, taxes or penalties associated with this Option if, in fact, the IRS were to determine that this Option constitutes deferred compensation under Section 409A of
the Code. You should consult with your own tax advisor concerning the tax consequences of such a determination by the IRS. 
 6.
Withholding of Taxes. The Company shall be entitled, if necessary or desirable, to deduct and withhold from you, from any amounts due and payable by the Company to you (or secure payment from you in lieu of withholding), the amount of any
withholding or other tax due in connection with the issuance, vesting, ownership, modification, adjustment, disposition, exercise or otherwise with respect to your Option or the securities issuable under your Option, and the Company may defer the
issuance of shares of Common Stock under your Option unless you make arrangements satisfactory to the Company for your payment of such amounts or indemnification of the Company with respect to such matters. In the event that the Company does not
make such deductions or withholdings, you shall indemnify the Company for and remain responsible for any amounts paid or payable by the Company with respect to any such taxes, together with any interest, penalties and additions to tax and any
related expenses thereto. 
 7. Adjustments. In the event of a reorganization, recapitalization, stock dividend or stock split, or
combination or other change in the shares of Common Stock, the Committee shall make such adjustments in the number and type of securities authorized by the Plan, the number and type of securities covered by your Option and the Exercise Price
specified herein as the Committee may determine to be appropriate and equitable. 
 8. Miscellaneous. 

(a) Amendment. Except as otherwise provided herein, any provision of this Agreement may be amended or waived only with the prior written
consent of you and the Company. This Agreement may also be amended as provided under the Plan, but no such amendment shall adversely effect your rights under this Agreement without your written consent, unless otherwise permitted by the Plan. 

(b) Successors and Assigns. Except as otherwise expressly provided herein, all covenants and agreements contained in this Agreement by
or on behalf of any of the parties hereto shall bind and inure to the benefit of the respective successors and permitted assigns of the parties hereto whether so expressed or not. 

(c) Severability. Whenever possible, each provision of this Agreement (including, Exhibit A and Exhibit B attached hereto)
shall be interpreted in such manner as to be effective and valid under applicable law, but if any provision of this Agreement is held to be prohibited by or invalid under applicable law, such provision shall be ineffective only to the extent of such
prohibition or invalidity, without invalidating the remainder of this Agreement. 
 (d) Counterparts and Delivery by Facsimile or
Email. This Agreement and any agreement or instrument entered into in connection with this Agreement, and any amendments hereto or thereto, may be executed in separate counterparts, each of which is deemed to be an original and all of which
taken together constitute one and the same agreement, and, to the extent signed and delivered by means of a facsimile machine or email (including by an attachment thereto (e.g., PDF)), shall be treated in

  
 4 

 
all manner and respects as an original agreement or instrument and shall be considered to have the same binding legal effect as if it were the original signed version thereof delivered in person.
At the request of any party hereto or to any such agreement or instrument, each other party hereto or thereto shall re-execute original forms thereof and deliver them to all other parties. No party hereto or
to any such agreement or instrument shall raise the use of a facsimile machine or email (including by an attachment thereto (e.g., PDF)) to deliver a signature or the fact that any signature or agreement or instrument was transmitted or communicated
through the use of a facsimile machine or by email as a defense to the formation of a contract and each such party forever waives any such defense. 

(e) No Strict Construction. The language used in this Agreement shall be deemed to be the language chosen by the parties hereto to
express their mutual intent, and no rule of strict construction shall be applied against any party. 
 (f) Construction;
Determinations. This Agreement is granted pursuant to the Plan and is, in all respects, limited by and subject to the express provisions of the Plan, as amended from time to time. The interpretation and construction by the Committee of the Plan,
this Agreement and any such rules and regulations adopted by the Committee for purposes of administering the Plan, shall be final, conclusive and binding upon you and all other Persons. The descriptive headings of the sections of this Agreement are
for convenience only and do not constitute a part of this Agreement. The definitions of terms herein shall apply equally to the singular and plural forms of the terms defined. Whenever the context may require, any pronoun shall include the
corresponding masculine, feminine and neuter for Ms. The words “include”, “includes” and “including” shall be deemed to be followed by the phrase “without limitation”. Unless the context requires
otherwise (i) any definition of or reference to any agreement, instrument or other document herein shall be construed as referring to such agreement, instrument or other document as from time to time amended, supplemented or otherwise modified
(subject to any restrictions on such amendments, supplements or modifications set forth herein), (ii) any reference herein to any Person shall be construed to include such Person’s successors and assigns, (iii) the words
“herein”, “hereof” and “hereunder”, and words of similar import, shall be construed to refer to this Agreement in its entirety and not to any particular provision hereof and (iv) all references herein to
sections shall be construed to refer to sections of this Agreement unless otherwise noted. 
 (g) Governing Law. Any issues,
disputes or claims arising out of or in connection with this Agreement and all issues and questions concerning the construction, validity, enforcement and interpretation of this Agreement shall be governed by and construed in accordance with the
laws of the State of Delaware, without giving effect to any choice of law or conflict of law rules or provisions (whether of the State of Delaware or any other jurisdiction) that would cause the application of the laws of any jurisdiction other than
the State of Delaware.  
 (h) Notices. Any communication or notice required or permitted to be given hereunder shall be in
writing, and, if to the Company, to its principal place of business, attention: Chief Executive Officer, and, if to you, to the address appearing on the records of the Company. Such communication or notice shall be delivered personally or by a
reputable overnight delivery service. Any such notice shall be deemed given when received by the intended recipient. Notwithstanding the foregoing, any notice required or permitted hereunder from the Company to you may be made by electronic means,
including by electronic mail to your Company-maintained electronic mailbox, and you hereby consent to receive such notice by electronic delivery. To the extent permitted in an electronically delivered notice described in the previous sentence, you
shall be permitted to respond to such notice or communication by way of a responsive electronic communication, including by electronic mail. 

(i) Waiver of Section 220 of the DGCL. You acknowledge and understand that, but for the waiver made herein, you would
be entitled, upon written demand under oath stating the purpose 

  
 5 

 
thereof, to inspect for any proper purpose, and to make copies and extracts from, the Company’s stock ledger, a list of its stockholders, and its other books and records, and the books and
records of subsidiaries of the Company, if any, under the circumstances and in the manner provided in Section 220 of the General Corporation Law of Delaware (any and all such rights, and any and all such other rights of yours as may be provided
for in Section 220, the “Inspection Rights”). In light of the foregoing, until the first sale of Common Stock of the Company to the general public pursuant to a registration statement filed with and declared effective by the
Securities and Exchange Commission under the Exchange Act, you hereby unconditionally and irrevocably waive the Inspection Rights, whether such Inspection Rights would be exercised or pursued directly or indirectly pursuant to Section 220 or
otherwise, and covenants and agrees never to directly or indirectly commence, voluntarily aid in any way, prosecute, assign, transfer, or cause to be commenced any claim, action, cause of action, or other proceeding to pursue or exercise the
Inspection Rights. 
 (j) Restrictive Covenants. As a condition to this Agreement and to eligibility, receipt or retention of the
payments, rights and benefits in respect of the Options awarded hereunder, you agree to those additional terms set forth on Exhibit B, which are hereby incorporated by reference and which shall survive termination of your service or
employment with the Company or any Affiliates 
 (k) WAIVER OF JURY TRIAL; JURISDICTION. NO PARTY TO THIS AGREEMENT OR ANY ASSIGNEE,
SUCCESSOR, HEIR OR PERSONAL REPRESENTATIVE OF A PARTY SHALL SEEK A JURY TRIAL IN ANY LAWSUIT, PROCEEDING, COUNTERCLAIM OR ANY OTHER LITIGATION PROCEDURE BASED UPON OR ARISING OUT OF THIS AGREEMENT OR ANY OF THE OTHER AGREEMENTS OR THE DEALINGS OR
THE RELATIONSHIP BETWEEN THE PARTIES. NO PARTY WILL SEEK TO CONSOLIDATE ANY SUCH ACTION, IN WHICH A JURY TRIAL HAS BEEN WAIVED, WITH ANY OTHER ACTION IN WHICH A JURY TRIAL CANNOT OR HAS NOT BEEN WAIVED. THE PROVISIONS OF THIS PARAGRAPH HAVE BEEN
FULLY DISCUSSED BY THE PARTIES HERETO, AND THESE PROVISIONS SHALL BE SUBJECT TO NO EXCEPTIONS. THE PARTIES AGREE THAT ANY ACTIONS OR PROCEEDINGS ARISING IN CONNECTION WITH THIS AGREEMENT SHALL BE TRIED AND LITIGATED EXCLUSIVELY IN THE FEDERAL OR
STATE COURTS LOCATED IN COOK COUNTY, ILLINOIS. NEITHER PARTY HAS IN ANY WAY AGREED WITH OR REPRESENTED TO ANY OTHER PARTY THAT THE PROVISIONS OF THIS PARAGRAPH WILL NOT BE FULLY ENFORCED IN ALL INSTANCES. 

(l) Entire Agreement. This Agreement and the Plan constitute the entire understanding between you and the Company, and supersedes all
other agreements, whether written or oral, with respect to the acquisition by you of Common Stock of the Company. 

*    *    *    *    * 

  
 6 

 Please execute the extra copy of this Agreement in the space below and return it to the
Company’s at its executive offices to confirm your understanding and acceptance of the agreements contained in this Agreement. 
  

			
	Very truly yours,
	
	CASTLE CREEK BIOSCIENCES, INC.
		
	By:	 	  

		
	Its:	 	 General Counsel

 The undersigned hereby acknowledges having read this Agreement and the Plan and hereby agrees to be
bound by all provisions set forth herein and in the Plan. 
  

							
	Dated as of:	 		 	                          	 	PARTICIPANT
				
	                        	 		 		 	  

		 		 		 	Name:

 Exhibit A 

OPTION EXERCISE NOTICE 
 The
undersigned is the holder of an option (the “Option”) to acquire ________ shares of Common Stock in Castle Creek Biosciences, Inc. (the “Company”) granted pursuant to that certain Stock Option Agreement, dated as of
_____________ (the “Stock Option Agreement”). Capitalized terms used and not otherwise defined in this option exercise notice shall have the meaning given to such terms in the Plan. Subject to the further conditions of
Section 3 of the Stock Option Agreement, the undersigned hereby exercises the Option with respect to                  shares of Common
Stock for an aggregate exercise price of $                , payable in accordance Section 2(b) of the Stock Option Agreement. 

In connection with the foregoing exercise of the Option, the undersigned represents and acknowledges to the Company as follows: 

 

	1)	 He or she has received a copy of the Plan and has read and understands the Plan. 

 

	2)	 He or she has executed a joinder to all stockholders, financing, and related agreements provided by the
Company. 

  

	3)	 The shares of Common Stock are subject to transfer restrictions set forth in one or more stockholders’
agreements and are subject to repurchase pursuant to the terms of the Stock Option Agreement and/or Plan. 

  

	4)	 The shares of Common Stock have not been registered under the Exchange Act and are offered pursuant to an
exemption thereunder and that such shares of Common Stock have not been approved or disapproved by the Securities and Exchange Commission or by any other Federal or state agency. 

 

	5)	 The shares of Common Stock acquired upon exercise of the Option are being acquired for investment purposes, and
not on behalf or for the benefit of any other person, trust, estate or business organization, and the undersigned has no intention of distributing any shares of Common Stock to others in violation of the Exchange Act. 

 

	6)	 There are no existing circumstances which will compel the undersigned to obtain money by the sale of any shares
of Common Stock, and the undersigned has no reason to anticipate any change in such undersigned’s circumstances, financial or otherwise, or to anticipate any occasion or event, which would cause the undersigned to assign, transfer, sell or
distribute, or necessitate or require the undersigned to assign, transfer, sell or distribute, any shares of Common Stock. The undersigned understands that the shares of Common Stock are illiquid and that the undersigned may be required to hold the
shares of Common Stock indefinitely. 

  

	7)	 The shares of Common Stock may also be subject to resale restrictions imposed by the securities laws of various
states and may not be sold without compliance with such laws. 

  

	8)	 The undersigned is a resident of the State of
                . 

  

	9)	 The undersigned is responsible for the tax consequences relating to the exercise of the Option.

  

							
	Executed this ____ day of ______________.	 		 		 	  

		 		 		 	Name: ______________

  
 8 

 EXHIBIT B 

ADDITIONAL TERMS 

(a) Acknowledgements. Capitalized terms used in this Exhibit B and not elsewhere defined in the Stock Option Agreement to which
this Exhibit B is attached (the “Agreement”) shall have the meanings set forth in paragraph (j) of this Exhibit B. This Exhibit B is intended to apply in addition to and not in lieu of any similar covenant
or term in the Participant’s employment or services agreement, offer letter or similar document or other arrangement with the Company or any of its direct or indirect Affiliates or subsidiaries (the Company and its direct or indirect Affiliates
and subsidiaries are collectively referred to herein, the “Company Group”), and by signing the Agreement the Participant acknowledges and agrees to same. The Participant acknowledges that the Participant has been advised by the
Company that the restrictions and covenants contained in this Exhibit B, and the Participant’s agreement to such restrictions and covenants, constitute a material inducement to the Company to execute the Agreement, to provide the
Participant with the Option pursuant to the Agreement to which this Exhibit is attached and to issue the Common Stock issuable upon the exercise thereof. The Participant acknowledges that participation in the Plan and eligibility for the Option and
the Common Stock issuable upon the exercise thereof constitute sufficient consideration for the promises and agreements made by the Participant hereunder, which shall survive the termination of the Participant’s employment or service with the
Company Group. The Participant acknowledges that: (i) as a result of the Participant’s employment or service with the Company Group, the Participant has obtained and will continue to obtain Confidential Information (as defined below); (ii)
the Confidential Information, and each element or aspect thereof, has been developed and created by the Company Group at substantial time and expense; (iii) the Confidential Information constitutes valuable proprietary assets of the Company
Group, the Company Group’s reservation of rights and control of Confidential Information is of significant competitive importance and commercial value to the Company Group, and the Company Group will suffer substantial damage and irreparable
harm which will be difficult to compute if, during the period of employment or service or thereafter, the Participant discloses or improperly uses any such Confidential Information in violation of the provisions of this Exhibit B;
(iv) the nature of the Company Group’s business is such that it is highly competitive and could be conducted anywhere in the world and is not limited to any particular geographic scope or region(s); (v) the Company Group will suffer
substantial damage and irreparable harm which will be difficult to compute if, during the period of employment or service or thereafter, the Participant should solicit or interfere with any individual employed by or providing services to any of the
Company Group or their investment opportunities, acquisition targets, financing sources, suppliers or customers in violation of this Exhibit B; (vi) the provisions of this Exhibit B are reasonable and necessary for the protection
of the legitimate business interests of the Company Group; (vii) the provisions of this Exhibit B will not preclude the Participant from other gainful employment or service following the termination of his or her services to the Company
Group; (viii) the Confidential Information constitutes a protectable business interest of the Company Group; (ix) that Confidential Information is vital, sensitive, confidential and proprietary to the Company Group; and (x) a breach
by the Participant of this Exhibit B would result in losses to the Company Group for which remedies at law are inadequate, and would result in the expenditure of additional financial costs, loss of business advantage and opportunities,
potential liability under confidentiality obligations with third parties and potential civil and criminal penalties. 
 (b) Obligation to
Maintain Confidentiality. The Participant acknowledges that the information, observations and data obtained by the Participant during the course of the Participant’s service with the Company Group concerning the business and affairs of the
Company Group, including, but not limited to, information concerning acquisition opportunities in or reasonably related to the business of the Company Group (“Confidential Information”), of which the Participant becomes aware during
the Participant’s service with the Company Group are the property of the Company Group. 

  
 9 

 
Therefore, the Participant agrees not to disclose to any unauthorized Person or use for Participant’s own account any Confidential Information without the Board’s written consent,
unless and to the extent that the aforementioned matters (i) become generally known to and available for use by the public other than as a result of the Participant’s acts or omissions in breach of this Agreement, (ii) were known by
the Participant prior to the Participant’s commencement of service with the Company Group (other than Confidential Information disclosed to the Participant in confidence in connection with the Participant’s employment with Company or
another member of the Company Group), or (iii) is required to be disclosed pursuant to any applicable law or court order. The Participant agrees to deliver to the Company upon the Participant’s termination of service with the Company
Group, or at any other time the Company may request in writing, all memoranda, notes, plans, records, reports and other documents (and copies thereof) relating to the business of the Company Group (including, without limitation, all acquisition
prospects, lists and contact information) or containing Confidential Information which he may then possess or have under his control. 
 (c)
Third Party Information. The Participant understands that the Company Group will receive from third parties confidential or proprietary information (“Third Party Information”) subject to a duty on the part of the Company
Group to maintain the confidentiality of such information and to use it only for certain limited purposes. The Participant will hold Third Party Information in strictest confidence and will not disclose to anyone (other than personnel, consultants,
attorneys, accountants and other advisors of the Company Group who need to know such information in connection with their work for the Company Group) or use such Third Party Information, except to the extent that (i) such Third Party
Information shall have become generally known to and available for use by the public other than as a result of Participant’s acts or omissions in breach of this Agreement, (ii) such Third Party Information is required to be disclosed
pursuant to any applicable law or court order, or (iii) the disclosure of such Third Party Information is expressly authorized by the Board in writing. 

(d) Inventions and Patents. The Participant hereby assigns to the Company Group all right, title and interest to all patents and patent
applications, all inventions, innovations, improvements, developments, methods, designs, analyses, drawings, reports and all similar or related information (in each case whether or not patentable), all copyrights and copyrightable works, all trade
secrets, confidential information and know-how, and all other intellectual property rights that both (i) are or were conceived, reduced to practice, developed or made by the Participant while employed by,
or in service to, the Company Group and (ii) that (A) relate to the actual or anticipated business, research and development or existing or future products or services of the Company Group, or (B) are or were conceived, reduced to
practice, developed or made using any of the equipment, supplies, facilities, assets or resources of the Company Group (including, but not limited to, any intellectual property rights) (“Work Product”). The Participant shall
promptly disclose such Work Product to the Company Group and perform all actions reasonably requested by the Company Group to establish and confirm the Company Group’s ownership thereof (including, without limitation, assignments, consents,
powers of attorney, applications and other instruments). 
 (e) Noncompetition, Nonsolicitation and Nondisparagement. The Participant
acknowledges that in the course of the Participant’s service with Company Group the Participant will become familiar with trade secrets and other confidential information concerning the Company Group and that the Participant’s services
will be of special, unique and extraordinary value to the Company and the other members of the Company Group. Therefore, the Participant agrees that: 

  
 10 

	 	(i)	 From the Date of Grant specified above through the first
(1st) anniversary of the termination of the Participant’s service with the Company Group (the “Restricted Period”), the Participant shall not, anywhere in the world,
directly or indirectly (A) own, manage, control, participate in, consult with, render services for, or in any manner engage in any business that is a Competing Business as of the relevant date of determination, (B) interfere with any
business relation of the Company Group, or (C) usurp any business opportunity of the Company Group that the Participant learned of while providing services to the Company Group or while a party to this Agreement. Nothing herein shall prohibit
the Participant from being a passive owner of not more than 5% of the outstanding stock of any class of any entity that is publicly traded, so long as the Participant has no active participation in the business of such entity. For purposes of this
Agreement, the relevant date of determination shall mean (A) the date upon which the Participant commences to engage in such activity with respect to any activity commenced during the Participant’s employment with or other service to the
Company Group, or (y) the date of termination of the Participant’s service with the Company Group (the “Termination Date”) with respect to any activity the Participant commences to engage in after the Termination Date.

  

	 	(ii)	 During the Restricted Period, the Participant shall not directly or indirectly through another entity
(A) induce or attempt to induce any employee of the Company Group to leave the employ of any member of the Company Group or (B) hire any such employee or any person who was employed by or providing services for the Company Group at any
time during the twelve (12) months preceding the commencement of the Restricted Period. 

  

	 	(iii)	 During the Participant’s service to the Company Group and continuing after the termination of such service
(regardless of the reason for such termination), the Participant will not, whether in private or in public including through social media, whether directly or indirectly, make, publish, encourage, ratify or authorize, or assist or enable any other
person or entity to make, authorize, ratify or publish, any statements that in any way defame, criticize, malign, impugn, reflect negatively on, or disparage any of member of the Company Group or investors, or their respective employees, directors,
officers or managers, or that place any such persons or entities in a negative light in any manner whatsoever.     

(f) Reporting Exception. Nothing in this Agreement prohibits the Participant from reporting possible violations of federal law or
regulation to any governmental agency or entity, or making other disclosures, that are protected under the whistleblower provisions of federal law or regulation (or similar state laws). The Participant will not need the prior authorization of the
Committee to make any such reports or disclosures and the Participant will not be required to notify the Company that the Participant has made such reports or disclosures, provided, that nothing shall waive any attorney client or similar privilege
of the Company Group. Nothing in this Agreement in any way prohibits or is intended to restrict or impede the Participant from exercising protected rights to the extent that such rights cannot be waived by agreement. The Participant will not be held
criminally or civilly liable under any federal or state trade secret law for any disclosure of a trade secret that is made: (A) in confidence to a federal, state or local government official, either directly or indirectly, or to an attorney and
solely for the purpose of reporting or investigating a suspected violation of law, or (B) in a complaint or other document that is filed under seal in a lawsuit or other proceeding. If the Participant files a lawsuit for retaliation by any of
the Company Group for reporting a suspected violation of law, the Participant may disclose the Company Group’s trade secrets to the Participant’s attorney and use the trade secret information in the court proceeding if the Participant
(x) files any document containing the trade secret under seal and (y) does not disclose the trade secret, except pursuant to court order. 

  
 11 

 (g) Enforcement and Acknowledgments. 

 

	 	(i)	 If, at the time of enforcement of the provisions of this Exhibit B, a court or an arbitrator shall hold
that the duration, scope or area restrictions stated therein are unreasonable under the circumstances then existing, the parties agree that the maximum duration, scope or area reasonable under such circumstances shall be substituted for the stated
duration, scope or area and that the court or arbitrator shall be allowed to revise the restrictions contained herein to cover the maximum period, scope and area permitted by law. Because the Participant’s services are unique and because the
Participant has access to Confidential Information, the parties hereto agree that money damages would be an inadequate remedy for any breach of the provisions of this Exhibit B. Therefore, in the event a breach or threatened breach of this
Agreement, the Company Group and its successors or permitted assigns may, in addition to other rights and remedies existing in their favor, apply to any court of competent jurisdiction for specific performance and/or injunctive or other relief in
order to enforce, or prevent any violations of, the provisions hereof (without posting a bond or other security). 

  

	 	(ii)	 The Participant acknowledges, both on his or her behalf and on behalf of his or her successors and assigns),
that the Option is subject to the Plan including, but not limited to, Article 11 thereof and that the provisions of this Exhibit B are in consideration of the grant of the Option hereunder, the Common Stock issuable upon the exercise thereof
and additional good and valuable consideration as set forth in this Agreement. In addition, the Participant agrees and acknowledges that the restrictions contained in this Exhibit B do not preclude the Participant from earning a livelihood,
nor do they unreasonably impose limitations on the Participant’s ability to earn a living. In addition, the Participant acknowledges (A) that the Business is and will be international in scope and without geographical limitation,
(B) notwithstanding the state of incorporation or principal office of the Company or any other member of the Company Group, it is expected that the Company Group have and will have business activities and valuable business relationships within
its industry throughout the world, and (C) as part of his or her responsibilities, the Participant may be traveling around the world in furtherance of the Company Group’s business and relationships. The Participant agrees and acknowledges
that the potential harm to the Company Group of the non-enforcement of this Exhibit B outweighs any potential harm to the Participant of their enforcement by injunction or otherwise. The Participant
acknowledges that he or she has carefully read this Agreement and has given careful consideration to the restraints imposed upon the Participant by this Agreement (including, but not limited to, this Exhibit B), and is in full accord
as to their necessity for the reasonable and proper protection of Confidential Information. The Participant expressly acknowledges and agrees that each and every restraint imposed by this Agreement is reasonable with respect to subject matter, time
period and geographical area. 

 (h) Remedies. The Participant agrees that, in the event of any actual or threatened
breach by the Participant of any covenant set forth in this Agreement and/or this Exhibit B, upon written notice from the Company, (i) the Option (including, any Common Stock issued or issuable upon the exercise thereof (whether held by
the Participant, his or her estate or any transferee) shall automatically be forfeited, terminated and cancelled for no consideration whatsoever and without any further action by the Company, and (ii) any amounts previously paid to the
Participant (or his or her estate or any transferee) with respect to the Option or any Common Stock issued or issuable upon the exercise thereof shall be repaid immediately to the Company. 

  
 12 

 (i) Relief. The Participant further acknowledges that the other members of the
Company Group are third party beneficiaries of the Agreement and this Exhibit B and will be irreparably harmed if such covenants are not specifically enforced. Accordingly, the Participant agrees that in addition to any other relief to which
the Company Group may be entitled, in law or equity, they shall be entitled to obtain injunctive relief (without the requirement of posting a bond or other security) from a court of competent jurisdiction, for the purpose of restraining the
Participant from an actual or threatened breach of any such covenants. Participant also acknowledges that the remedies afforded pursuant to this paragraph (i) are not exclusive, nor shall they preclude any member of the Company Group from
seeking or receiving any other relief, including without limitation, any form of monetary or other equitable relief. Upon the reasonable request by any member of the Company Group, the Participant shall provide reasonable assurances and evidence of
compliance with the terms of this Agreement and this Exhibit B. In the event that injunctive relief or specific enforcement of the Participant’s obligations hereunder is required, the Participant will (i) indemnify and hold the
Company Group harmless with respect to any damages (whether actual or otherwise), actions, losses, costs and liabilities arising from the Participant’s breach of the Participant’s obligations under the Agreement or this Exhibit B,
including providing an accounting (and provide such information as is reasonably necessary for the Company to create or confirm such accounting) and disgorging any profits, gains or other windfalls resulting directly or indirectly from such breach,
and (ii) reimburse or pay on demand the Company Group, as applicable, for fees and costs incurred by them (including, without limitation, reasonable attorneys’ fees and costs) in obtaining such injunctive relief or specific enforcement
and/or in seeking such damages. 
 (j) Definitions. For purposes of this Exhibit B, the following definitions are applicable:

 “Business” means, at the relevant time, the licensing, acquisition, development, commercialization, distribution and
lifecycle management of pharmaceutical products in those therapeutic areas in which the Company Group is materially engaged. 

“Competing Business” means any business that competes with the Business. 

*** 

  
 13EX-10.9

 Exhibit 10.9 

Separation and Release of Claims Agreement 

This Separation and Release of Claims Agreement (“Agreement”) is entered into by and between Castle Creek Biosciences, Inc.,
a Delaware corporation (the “Employer”), on behalf of itself, its parent(s), subsidiaries, and other corporate affiliates, and each of their respective present and former executives, officers, directors, owners, shareholders, and
agents, individually and in their official capacities (collectively referred to as the “Employer Group”), and John Maslowski (the “Executive”) (Employer and the Executive are collectively referred to as the
“Parties”) as of May 31, 2021 (the “Execution Date”). 
 The Executive’s last day of employment
with the Employer was May 31, 2021 (the “Separation Date”). After the Separation Date, the Executive will not represent himself as being an executive, officer, attorney, agent, or representative of the Employer Group for any
purpose. Except as otherwise set forth in this Agreement, the Separation Date is the employment termination date for the Executive for all purposes, meaning the Executive is not entitled to any further compensation, monies, or other benefits from
the Employer Group including coverage under any benefit plans or programs sponsored by the Employer, as of the Separation Date, except as set forth in and subject to Paragraph 3 below. 

1. Return of Property. By the Separation Date, the Executive warrants and represents that he has returned all Employer
property, including identification cards or badges, access codes or devices, keys, laptops, computers, telephones, mobile phones, hand-held electronic devices, credit cards, electronically stored documents or files, physical files, and any other
Employer property in the Executive’s possession. 
 2. Executive Representations. The Executive specifically represents,
warrants, and confirms that the Executive: 
  

	 	(a)	 has not filed any claims, complaints, or actions of any kind against the Employer Group with any federal,
state, or local court or government or administrative agency; 

  

	 	(b)	 has not made any claims or allegations to the Employer Group related to sexual harassment, sex discrimination,
or sexual abuse, and that none of the payments set forth in this Agreement are related to sexual harassment, sex discrimination, or sexual abuse; 

  

	 	(c)	 has been properly paid for all hours worked for the Employer and; 

 

	 	(d)	 has received all salary, wages, commissions, bonuses, and other compensation due to the Executive outside of
this Agreement, with the exception of the Executive’s final payroll check for salary through and including the Separation Date, which will be paid on the next regularly scheduled payroll date for the pay period including the Separation Date;
and 

	 	(e)	 has not engaged in and is not aware of any unlawful conduct relating to the business of the Employer or
Employer Group. 

 3. Separation Benefits. As consideration for the Executive’s execution
of, non-revocation of, and compliance with this Agreement, including the Executive’s Waiver and Release of claims in Paragraph 4 and Executive’s Amended and Restated Employment Agreement entered into
on August 20, 2019, together with the General Release in Exhibit A to the Amended and Restated Employment Agreement, which Executive signed on May 31, 2021 (the “Employment Agreement”), the Employer agrees to provide the
following severance and benefits pursuant to Paragraph 5.2 of the Employment Agreement: 
  

	 	(a)	 An amount equal to one and a half (1.5) times the sum of (i) the Executive’s Base Salary and
(ii) the Executive’s target Annual Bonus, which equals $1,009,562 in the aggregate, less all relevant taxes and other withholdings, which shall be paid in substantially equal installments over the remaining portion of calendar year
2021 in accordance with the Employer’s normal payroll practices. The installments shall commence on the first normal payroll date that is at least five (5) business days after the Effective Date (as defined in Section 4(b)(vii)), and
the initial installment shall include a catch-up amount to cover any unpaid installments during the period from the Separation Date until the date of such first installment, if applicable;

  

	 	(b)	 An amount equal to eleven (11) vacation days which were accrued but not used by the Executive, which
equals $18,982.48, less all relevant taxes and other withholdings, which shall be paid together with the first installment referenced in Paragraph 3 (a) above. 

 

	 	(c)	 If the Executive and his eligible dependents timely and properly elect COBRA continuation coverage, the
Employer shall reimburse the Executive an amount equal to 100% of the monthly COBRA premium paid by the Executive for him and his eligible dependents, for either (18) months following the Separation Date, or, if earlier, until the date the
Executive becomes eligible to receive coverage from another employer or is otherwise no longer eligible to receive (or no longer elects) COBRA continuation coverage. Such COBRA reimbursements shall be made on a taxable basis and shall commence on
the first normal payroll date that is at least five (5) business days after the Effective Date, provided that the initial reimbursement shall include a catch-up amount to cover any unpaid monthly
reimbursements during the period from the Separation Date until the date of such first installment; and 

  
 2 

	 	(d)	 That certain option held by the Executive to purchase 5,500 shares of the Employer’s common stock, which
was granted on October 1, 2020 with an exercise price of $52.61 per share (the “Option”), pursuant to the Employer’s Amended and Restated Management Incentive Plan (the “Incentive Plan”) and that certain
Stock Option Agreement, dated as of October 1, 2020 between the Employer and the Executive (the “Option Agreement”) shall be fully vested and exercisable as of the Separation Date, and following the Separation Date shall remain
exercisable as follows: 

  

	 	(i)	 If a Registration Statement on Form S-1 filed with the Securities and
Exchange Commission relating to the registered underwritten public offering of shares of common stock of Castle Creek Biosciences, Inc. (an “S-1”) has become effective by December 31,
2021, the Option shall remain exercisable until the earlier of (x) the date which is three (3) months after the lock-up agreement entered into by Executive in connection with such public offering has
expired or (y) the “Expiration Date” of the Option as set forth in the Option Agreement. 

  

	 	(ii)	 If an S-1 has not become effective by December 31, 2021, the
Option shall remain exercisable until the earlier of (x) December 31, 2021 or (y) the “Expiration Date” of the Option as set forth in the Option Agreement. 

The Executive acknowledges and agrees that the Executive’s only equity or equity-based interest, or right to any equity or equity-based
interest, in the Employer or any of its affiliates consists solely of the Option. Other than as modified by clauses (i) and (ii) above, the Option shall remain subject in all respects to the terms and conditions of the Option Agreement and the
Incentive Plan. 
 The Executive understands, acknowledges, and agrees that these benefits exceed what the Executive is otherwise entitled
to receive on separation from employment, and that these benefits are being given as consideration in exchange for executing this Agreement, including the General Release contained in Paragraph 4 of the Agreement and the restrictive covenants
contained in it. The Executive acknowledges and agrees that the General Release dated May 31, 2021 in Exhibit A to the Amended and Restated Employment Agreement is incorporated herein and superseded by the General Release contained in Paragraph
4 of the Agreement. The Executive further acknowledges that the Executive is not entitled to any additional payment or consideration not specifically referenced in this Agreement. 

4. General Release. 
  

	 	(a)	 Executive’s General Release and Waiver of Claims 

In exchange for the consideration provided in this Agreement, the Executive and the Executive’s heirs, executors, representatives,
administrators, agents, insurers, and assigns (collectively, the “Releasors”) irrevocably and unconditionally fully and forever waive, release, and discharge the Employer and Employer Group, including the Employer’s parents,
subsidiaries, affiliates, divisions, predecessors, successors, and assigns, and each of its and their current or former respective 

  
 3 

 
officers, directors, executives, employees, agents, shareholders, employment benefit plans (and the administrators and fiduciaries of such plans), attorneys and/or owners, and their respective
successors and assigns, and any other person or entity claimed to be jointly or severally liable with the Employer or any of the aforementioned persons or entities, in their corporate and individual capacities (collectively, the “Released
Parties”), from any and all claims, demands, actions, causes of actions, judgments, rights, fees, damages, debts, obligations, liabilities, and expenses (inclusive of attorneys’ fees) of any kind whatsoever, whether known or unknown
(collectively, “Claims”), that Releasors may have or have ever had against the Released Parties, or any of them, arising out of, or in any way related to the Executive’s hire, benefits, employment, termination, or separation
from employment with the Employer or Employer Group by reason of any actual or alleged act, omission, transaction, practice, conduct, occurrence, or other matter from the beginning of time up to and including the date of the Executive’s
execution of this Agreement, including, but not limited to: 
  

	 	(i)	 any and all claims under Title VII of the Civil Rights Act of 1964 (Title VII), as amended, 42 U.S.C.
§§ 2000 et. seq.; the Americans with Disabilities Act of 1990 (ADA), 42 U.S.C. §§ 12101 et. seq.; the Family and Medical Leave Act of 1993 (FMLA), as amended, 29 U.S.C. §§ 2601, et. seq.; (regarding
existing but not prospective claims), the Fair Labor Standards Act (FLSA); the Equal Pay Act; the Executive Retirement Income Security Act of 1974 (ERISA) (regarding unvested benefits), as amended , 29 U.S.C. §§ 1001, et. seq.; the
Civil Rights Act of 1991; Section 1981 of U.S.C. Title 42; the Fair Credit Reporting Act (FCRA); the Worker Adjustment and Retraining Notification Act of 1988 (WARN), as amended, 29 U.S.C. §§ 2101 et. seq.; the National Labor
Relations Act (NLRA); the Age Discrimination in Employment Act of 1967 (ADEA), as amended, 29 U.S.C. §§ 621, et seq.; the Older Workers Benefit Protection Act; the Uniform Services Employment and Reemployment Rights Act (USERRA);
the Genetic Information Nondiscrimination Act (GINA); the Immigration Reform and Control Act (IRCA); the Pennsylvania Human Relations Act (PHRA); the Pennsylvania Whistleblower Law, including any amendments and their respective implementing
regulations, and any other federal, state, local, or foreign law (statutory, regulatory, or otherwise) that may be legally waived and released; however, the identification of specific statutes is for purposes of example only, and the omission of any
specific statute or law shall not limit the scope of this general release in any manner; 

  
 4 

	 	(ii)	 any and all claims for compensation of any type whatsoever, including but not limited to claims for salary,
wages, bonuses, commissions, incentive compensation, vacation, and severance that may be legally waived and released, except the severance and benefits pursuant to this Agreement; 

 

	 	(iii)	 any and all claims arising under tort, contract, and quasi-contract law, including but not limited to claims of
breach of an express or implied contract, tortious interference with contract or prospective business advantage, breach of the covenant of good faith and fair dealing, promissory estoppel, detrimental reliance, invasion of privacy, nonphysical
injury, personal injury or sickness or any other harm, wrongful or retaliatory discharge, fraud, defamation, slander, libel, false imprisonment, and negligent or intentional infliction of emotional distress; and 

 

	 	(iv)	 any and all claims for monetary or equitable relief, including but not limited to attorneys’ fees, back
pay, front pay, reinstatement, experts’ fees, medical fees or expenses, costs and disbursements, punitive damages, liquidated damages, and penalties; and 

 

	 	(v)	 indemnification rights the Executive has against the Employer and Employer Group. 

However, this general release and waiver of claims excludes, and the Executive does not waive, release, or discharge:
(A) any right to file an administrative charge or complaint with, or testify, assist, or participate in an investigation, hearing, or proceeding conducted by the Equal Employment Opportunity Commission or other similar federal or state
administrative agencies, although the Executive waives any right to monetary relief related to any filed charge or administrative complaint; and (B) claims that cannot be waived by law, such as claims for unemployment benefit rights and
workers’ compensation; and (C) any right to file an unfair labor practice charge under the National Labor Relations Act; and (D) protections against retaliation under the Taxpayer First Act (26 U.S.C. § 2623(d)); and (E) any
rights to vested benefits, such as pension or retirement benefits, the rights to which are governed by the terms of the applicable plan documents and award agreements. 

(b) Specific Release of ADEA Claims 

In further consideration of the payments and benefits provided to the Executive in this Agreement, the Releasors hereby
irrevocably and unconditionally fully and forever waive, release, and discharge the Released Parties from any and all Claims, whether known or unknown, from the beginning of time through the date of the Executive’s execution of this Agreement
arising under the Age Discrimination in Employment Act of 1967, as amended, 29 U.S.C. §§ 621 et. seq., and its implementing regulations. By signing this Agreement, the Executive hereby acknowledges and confirms that: 

 

	 	(i)	 the Executive has read this Agreement in its entirety and understands all of its terms; 

  
 5 

	 	(ii)	 by this Agreement, the Executive has been advised in writing to consult with an attorney of the
Executive’s choosing and has consulted with such counsel before signing this Agreement; 

  

	 	(iii)	 the Executive knowingly, freely, and voluntarily agrees to all of the terms and conditions set out in this
Agreement including, without limitation, the waiver, release, and covenants contained in it; 

  

	 	(iv)	 the Executive is signing this Agreement, including the waiver and release, in exchange for good and valuable
consideration in addition to anything of value to which the Executive is otherwise entitled; 

  

	 	(v)	 the Executive was given at least twenty-one (21) days to consider
the terms of this Agreement and consult with an attorney of the Executive’s choice, although the Executive may sign it sooner if desired, and changes to this Agreement, whether material or immaterial, do not restart the running of the 21-day period; 

  

	 	(vi)	 the Executive understands that the Executive has seven (7) days after signing this Agreement to revoke the
release in this paragraph by delivering notice of revocation to Matthew Gantz, President and CEO of Castle Creek Biosciences, Inc., at 405 Eagleview Blvd., Exton, PA 19341 by email or overnight mail before the end of this seven-day period; and 

  

	 	(vii)	 the Executive understands that this Agreement shall not become effective until the eighth (8th) day after the
Executive signs, without revoking, this Agreement (“Effective Date”). No payments due to the Executive under this Agreement shall be made or begin before the Effective Date. 

 

	 	(c)	 Employer Release of Executive 

In exchange for the Releasors’ waiver and release of claims against the Released Parties, and non-revocation of any portion of that release, the Employer expressly waives and releases any and all claims against the Executive that may be waived and released by law with the exception of claims arising out of
or attributable to: (i) events, acts, or omissions taking place after the Parties’ execution of the Agreement; (ii) the Executive’s breach of any terms and conditions of the Agreement; and (iii) the Executive’s criminal
activities or intentional misconduct occurring during the Executive’s employment. 
 5. Knowing and Voluntary
Acknowledgment. The Executive specifically agrees and acknowledges that: 
  

	 	(a)	 the Executive has read this Agreement in its entirety and understands all of its terms; 

  
 6 

	 	(b)	 by this Agreement, the Executive has been advised to consult with an attorney before executing this Agreement[
and has consulted with such counsel as the Executive believed was necessary before signing this Agreement; 

  

	 	(c)	 the Executive knowingly, freely, and voluntarily assents to all of this Agreement’s terms and conditions
including, without limitation, the waiver, release, and covenants contained in it; 

  

	 	(d)	 the Executive is signing this Agreement, including the waiver and release, in exchange for good and valuable
consideration in addition to anything of value to which the Executive is otherwise entitled; 

  

	 	(e)	 the Executive is not waiving or releasing rights or claims that may arise after the Executive signs this
Agreement; and 

  

	 	(f)	 the Executive understands that the waiver and release in this Agreement is being requested in connection with
the Executive’s separation of employment from the Employer. 

 6. Post-Termination Obligations and Restrictive
Covenants. 
  

	 	(a)	 Acknowledgment 

The Executive understands and acknowledges that by virtue of the Executive’s employment with the Employer, the Executive
had access to and knowledge of Confidential Information, was in a position of trust and confidence with the Employer and benefitted from the Employer’s goodwill. The Executive understands and acknowledges that the Employer invested significant
time and expense in developing the Confidential Information and goodwill. 
 The Executive further understands and
acknowledges that the restrictive covenants below are necessary to protect the Employer’s legitimate business interests in its Confidential Information and goodwill. The Executive further understands and acknowledges that the Employer’s
ability to reserve these for the exclusive knowledge and use of the Employer is of great competitive importance and commercial value to the Employer and that the Employer would be irreparably harmed if the Executive violates the restrictive
covenants below. 
  

	 	(b)	 Confidential Information 

The Executive understands and acknowledges that during the course of employment with the Employer, the Executive has had access
to and learned about confidential, secret, and proprietary documents, materials, and other information, in tangible and intangible form, of and relating to the Employer Group and its businesses and existing and prospective customers, suppliers,

  
 7 

 
investors, and other associated third parties (“Confidential Information”). The Executive further understands and acknowledges that this Confidential Information and the
Employer’s ability to reserve it for the exclusive knowledge and use of the Employer is of great competitive importance and commercial value to the Employer, and that improper use or disclosure of the Confidential Information by the Executive
may cause the Employer to incur financial costs, loss of business advantage, liability under confidentiality agreements with third parties, civil damages, and criminal penalties. 

For purposes of this Agreement, Confidential Information includes, but is not limited to, all information not generally
known to the public, in spoken, printed, electronic, or any other form or medium, relating directly or indirectly to: all information respecting the business and activities of Castle Creek Biosciences or any predecessor or affiliates (the
“Company”), including, without limitation, the terms and provisions of this Agreement, the clients customers, suppliers employees, consultants, computer or other files, projects, products, computer disks or other media, computer
hardware or software programs, marketing plans, financial information, methodologies, know-how, processes, practices, approaches, projections, forecasts, formats, systems, data gathering methods and/or
strategies of the Company. 
 The Executive understands that the above list is not exhaustive, and that Confidential
Information also includes other information that is marked or otherwise identified or treated as confidential or proprietary, or that would otherwise appear to a reasonable person to be confidential or proprietary in the context and circumstances in
which the information is known or used. 
 The Executive understands and agrees that Confidential Information developed by
the Executive in the course of the Executive’s employment by the Employer is subject to the terms and conditions of this Agreement as if the Employer furnished the same Confidential Information to the Executive in the first instance.
Confidential Information shall not include information that is generally available to and known by the public at the time of disclosure to the Executive, provided that the disclosure is through no direct or indirect fault of the Executive or
person(s) acting on the Executive’s behalf. 
  

	 	(c)	 Disclosure and Use Restrictions 

 

	 	(i)	 Executive Covenants. The Executive agrees and covenants: 

 

	 	(A)	 to keep this Agreement and its terms confidential; 

 

	 	(B)	 to treat all Confidential Information as strictly confidential; 

 

	 	(C)	 not to directly or indirectly disclose, publish, communicate, or make available Confidential Information, or
allow it to be disclosed, published, communicated, or made available, in whole or part, to any entity or person whatsoever not 

  
 8 

	 	
having a need to know and authority to know and use the Confidential Information in connection with the business of the Employer or Employer Group, and, in any event, not to anyone outside of the
direct employ of the Employer Group except with the prior consent of an authorized officer acting on behalf of the Employer Group in each instance (and then, such disclosure shall be made only within the limits and to the extent of such duties or
consent); and 

  

	 	(D)	 not to access or use any Confidential Information, and not to copy any documents, records, files, media, or
other resources containing any Confidential Information, or remove any such documents, records, files, media, or other resources from the premises or control of the Employer, except as allowed by applicable law or with the prior consent of an
authorized officer acting on behalf of the Employer Group. 

 The Executive understands and acknowledges
that the Executive’s obligations under this Agreement regarding any particular Confidential Information begin immediately and shall continue after the Executive’s employment by the Employer until the Confidential Information has become
public knowledge other than as a result of the Executive’s breach of this Agreement or a breach by those acting in concert with the Executive or on the Executive’s behalf. 

 

	 	(ii)	 Permitted Disclosures. Nothing in this Agreement shall be construed to prevent disclosure of Confidential
Information as may be required by applicable law or regulation, or pursuant to the valid order of a court of competent jurisdiction or an authorized government agency, provided that the disclosure does not exceed the extent of disclosure required by
such law, regulation, or order. For example, nothing in this Agreement prohibits or restricts the Executive from filing a charge or complaint with the Securities and Exchange Commission (SEC), the Financial Industry Regulatory Authority (FINRA), or
any other securities regulatory agency or self-regulatory authority, or the Equal Employment Opportunity Commission (EEOC), the National Labor Relations Board (NLRB), the Occupational Safety and Health Administration (OSHA), or any other federal,
state, or local governmental agency or commission (collectively, “Government Agencies”). 

  

	 	(iii)	 Notice of Immunity Under the Defend Trade Secrets Act of 2016, 18 U.S.C. 1833(b). Notwithstanding any other
provision of this Agreement: 

  
 9 

	 	(A)	 The Executive will not be held criminally or civilly liable under any federal or state trade secret law for any
disclosure of a trade secret that is made: (1) in confidence to a federal, state, or local government official, either directly or indirectly, or to an attorney, and solely for the purpose of reporting or investigating a suspected violation of
law; or (2) in a complaint or other document that is filed under seal in a lawsuit or other proceeding. 

  

	 	(B)	 If the Executive files a lawsuit for retaliation by the Employer for reporting a suspected violation of law,
the Executive may disclose the Employer’s trade secrets to the Executive’s attorney and use the trade secret information in the court proceeding if the Executive: (1) files any document containing the trade secret under seal; and
(2) does not disclose the trade secret, except pursuant to court order. 

  

	 	(d)	 Non-Competition. 

Because of the Employer’s legitimate business interest as described in this Agreement and the good and valuable
consideration offered to the Executive, for twelve (12) months, beginning on the Separation Date (the “Restricted Period”), the Executive agrees and covenants that he will not, either directly or indirectly, as a proprietor,
partner, stockholder (except as the holder of not more than 1% of the outstanding stock of a publicly held company), director, executive, employee, consultant, joint venture, investor or in any other capacity, engage in, or own, manage, operate or
control, or participate in the ownership, management, operation or control of, any entity within the United States that engages (a) in the development, manufacture, marketing, distribution or sale of, or research directed to the development,
manufacture, marketing, distribution or sale of cellular biologic products or (b) in any other business activity carried on or planned to be carried on by Castle Creek Biosciences as of the Separation Date. Notwithstanding the forgoing, if
Castle Creek Biosciences is merged with or into a third party which is engaged in multiple lines of business, or if a party to multiple lines of business succeeds to Castle Creek Biosciences’s assets or business, then for purposes of this
paragraph, the term “Castle Creek Biosciences” shall mean and refer to the products and services being developed, manufactured, marketed, licensed, sold or provided by Castle Creek Biosciences immediately prior to such event and as it
subsequently develops and not to the third party’s other products and services. 
 Nothing in this Agreement prohibits
the Executive from purchasing or owning less than one percent (1%) of the publicly traded securities of any corporation, provided that the Executive’s ownership represents a passive investment and that the Executive is not a controlling person
of, or a member of a group that controls, the corporation. 

  
 10 

	 	(e)	 Non-Solicitation. 

The Executive understands and acknowledges that the Employer has expended and continues to expend significant time and expense
in developing customer relationships, customer information, and goodwill, and that because of the Executive’s experience with and relationship to the Employer Group, the Executive has had access to and learned about much or all of the Employer
Group’s customer information, such as names, phone numbers, addresses, email addresses, order history, order preferences, chain of command, pricing information, and other information identifying facts and circumstances specific to the customer
and relevant to the Employer’s services. The Executive understands and acknowledges that loss of any of these customer relationships or goodwill will cause significant and irreparable harm to the Employer. Likewise, the Executive understands
and acknowledges that the Employer has expended and continues to expend significant time and expense in recruiting and training its employees and that the loss of such employees would cause significant and irreparable harm to the Employer. 

Therefore, during the Restricted Period, the Executive shall not (except on the Company’s behalf), directly or indirectly,
on his own behalf or on behalf of any other person, firm, partnership, corporation or other entity, request any past, present or prospective customer of the Company (“Customer”) to curtail or cancel their business with the Company
or any of its predecessors or affiliates. After the Separation Date, a past or prospective Customer shall be limited to such Customer measured within the one (1) year period prior to the Separation Date. 

During the Restricted Period, the Executive also shall not (except on the Company’s behalf), directly or indirectly, on
his own behalf or on behalf of any other person, firm, partnership, corporation or other entity, contact, solicit, employ, interfere with, attempt to entice away from the Company any individual who is employed by the Company at the time of such
solicitation, employment, interference or enticement. During the Restricted Period, the Executive shall not (except on the Company’s behalf), directly or indirectly, on his own behalf or on behalf of any other person, firm, partnership,
corporation or other entity, request any Business Associate (as defined below) to curtail or cancel their business with the Company. “Business Associate” means any person which had had at any time during the Executive’s
employment a business relationship with the Company or the Employer Group, including without limitation, a sales representative, supplier, lender, borrower, guarantor, landlord, tenant, lessor, lessee, but excluding employees and Customers. 

7. Cooperation. The parties agree that certain matters in which the Executive has been involved during the Executive’s employment
may need the Executive’s cooperation with the Employer in the future. Accordingly, for a period of twelve (12) months after the Separation Date, to the extent reasonably requested by the Employer, the Executive shall cooperate with the
Employer regarding matters arising out of or related to the Executive’s service to the Employer. The Employer shall reimburse the Executive for reasonable expenses incurred in connection with this cooperation. The Executive understands that the
duties contemplated in this paragraph may be superseded by or subsumed within a future consulting agreement between the Company and the Executive, should one be entered into after the Separation Date. 

  
 11 

 8. Non-Disparagement. The Executive agrees
and covenants that the Executive shall not at any time make, publish, or communicate to any person or entity or in any public forum any defamatory, maliciously false, or disparaging remarks, comments, or statements concerning the Employer Group or
its businesses, or any of its Executives, officers, or directors and their existing and prospective customers, suppliers, investors, and other associated third parties, now or in the future. Employer agrees and covenants that its officers and
directors shall not at any time make, publish, or communicate to any person or entity or in any public forum any defamatory, maliciously false, or disparaging remarks, comments, or statements concerning the Executive now or in the future. 

This Paragraph does not in any way restrict or impede the Executive from exercising protected rights, to the extent that such rights cannot be
waived by agreement or from complying with any applicable law or regulation or a valid order of a court of competent jurisdiction or any Government Agency, provided that such compliance does not exceed that required by the law, regulation, or order.

 9. Remedies. In the event of a breach or threatened breach by the Executive of Paragraphs 6, 8, or 9 of this Agreement, Executive
hereby consents and agrees that money damages would not afford an adequate remedy and that Employer shall be entitled to seek a temporary or permanent injunction or other equitable relief against such breach or threatened breach from any court of
competent jurisdiction, without the necessity of showing any actual damages, and without the necessity of posting any bond or other security. Any equitable relief shall be in addition to, not in lieu of, legal remedies, monetary damages, or other
available relief. 
 In addition, if the Executive fails to comply with any of the terms of this Agreement or post-employment obligations
contained in it, the Employer may, in addition to any other available remedies, reclaim any amounts paid to the Executive under the provisions of this Agreement and terminate any benefits or payments that are later due under this Agreement, without
waiving the releases provided in it. 
 The Parties mutually agree that this Agreement can be specifically enforced in court and can be
cited as evidence in legal proceedings alleging breach of the Agreement. 
 10. Successors and Assigns. 

 

	 	(a)	 Assignment by the Employer or Employer Group 

The Employer or Employer Group may freely assign this Agreement at any time. This Agreement shall inure to the benefit of the Employer and/or
Employer Group and its successors and assigns. 
  

	 	(b)	 No Assignment by the Executive 

  
 12 

 The Executive may not assign this Agreement in whole or in part. Any purported assignment
by the Executive shall be null and void from the initial date of the purported assignment. 
 11. Governing Law, Jurisdiction, and
Venue. This Agreement and all matters arising out of or relating to this Agreement and the Executive’s employment or termination of employment, whether sounding in contract, tort, or statute, for all purposes shall be governed by and
construed in accordance with the laws of the Commonwealth of Pennsylvania, without regard to any conflicts of laws principles that would require the laws of any other jurisdiction to apply. Any action or proceeding by either of the Parties to
enforce this Agreement shall be brought only in any state or federal court located in the Commonwealth of Pennsylvania; if in state court, in the County of Chester, if in federal court, in the Eastern District of Pennsylvania. The Parties hereby
irrevocably submit to the exclusive jurisdiction of these courts and waive the defense of inconvenient forum to the maintenance of any action or proceeding in such venue. 

12. Entire Agreement. Unless specifically provided herein, this Agreement contains all of the understandings and representations
between Employer and Executive relating to the subject matter hereof and supersedes all prior and contemporaneous understandings, discussions, agreements, representations, and warranties, both written and oral, regarding such subject matter. In the
event of any inconsistency between this Agreement and any other agreement between the Executive and the Employer, the statements in this Agreement shall control. 

13. Modification and Waiver. No provision of this Agreement may be amended or modified unless the amendment or modification is agreed
to in writing and signed by the Executive and by the President and CEO of the Employer. No waiver by either Party of any breach by the other party of any condition or provision of this Agreement to be performed by the other Party shall be deemed a
waiver of any similar or dissimilar provision or condition at the same or any prior or subsequent time, nor shall the failure of or delay by either Party in exercising any right, power, or privilege under this Agreement operate as a waiver thereof
to preclude any other or further exercise thereof or the exercise of any other such right, power, or privilege. 
 14. Severability.
If any provision of this Agreement is found by a court or arbitral authority of competent jurisdiction to be invalid, illegal, or unenforceable in any respect, or enforceable only if modified, such finding shall not affect the validity of the
remainder of this Agreement, which shall remain in full force and effect and continue to be binding on the Parties. 
 15.
Interpretation. Captions and headings of the sections and paragraphs of this Agreement are intended solely for convenience and no provision of this Agreement is to be construed by reference to the caption or heading of any section or
paragraph. Moreover, this Agreement shall not be construed against either Party as the author or drafter of the Agreement. 
 16.
Counterparts. The Parties may execute this Agreement in counterparts, each of which shall be deemed an original, and all of which taken together shall constitute one and the same instrument. Delivery of an executed counterpart’s
signature page of this Agreement by facsimile, email in portable document format (.pdf), or by any other electronic means intended to preserve the original graphic and pictorial appearance of a document has the same effect as delivery of an executed
original of this Agreement. 

  
 13 

 17. No Admission of Liability. Nothing in this Agreement shall be construed as an
admission by the Employer or Employer Group of any wrongdoing, liability, or noncompliance with any federal, state, city, or local rule, ordinance, statute, common law, or other legal obligation. The Employer and Employer Group specifically
disclaims and denies any wrongdoing or liability to Executive. 
 18. Notices. All notices under this Agreement must be given in
writing by receipted email or overnight delivery at the addresses indicated in this paragraph. 
 Notice to Employer: 

Matthew Gantz 
 President and CEO

 Castle Creek Biosciences, Inc. 

405 Eagleview Blvd. 
 Exton, PA
19341 
 Notice to the Executive: 

John Maslowski 
 Address: 

19. Tolling. If the Executive violates any of the post-termination obligations in this Agreement, the obligation at issue will run from
the first date on which the Executive ceases to be in violation of such obligation. 
 20. Attorneys’ Fees and Costs. If the
Executive breaches any terms of this Agreement or the post-termination obligations articulated in it, to the extent authorized by Pennsylvania law, the Executive will be responsible for payment of all reasonable attorneys’ fees and costs that
Employer incurred in the course of enforcing the terms of this Agreement, including demonstrating the existence of a breach and any other contract enforcement efforts. 

21. Section 409A. The payments under this Agreement are intended to be exempt from or to comply with Section 409A of the Internal
Revenue Code of 1986, as amended (Section 409A), and this Agreement shall be construed and administered in accordance with such intent. The parties acknowledge and agree that they reasonably anticipate that the level of bona fide services the
Executive will perform for the Employer Group after the Separation Date as a consultant or as a director will permanent permanently decrease to no more than 20% percent of the average level of bona fide services performed by the Executive for the
Employer Group over the 36-month period immediately preceding the Separation Date and, accordingly, that the Executive’s termination of employment on the Separation Date shall constitute a
“separation from service” within the meaning of Section 409A. Notwithstanding the foregoing, Employer Group makes no representations that the payments and benefits provided under this Agreement are exempt from or comply with
Section 409A and in no event shall Employer or Employer Group be liable for all or any portion of any taxes, penalties, interest, or other expenses that may be incurred by Executive on account of
non-compliance with Section 409A. 

  
 14 

 22. Acknowledgment of Full Understanding. 

THE EXECUTIVE ACKNOWLEDGES AND AGREES THAT THE EXECUTIVE HAS FULLY READ, UNDERSTANDS, AND VOLUNTARILY ENTERS INTO THIS AGREEMENT. THE
EXECUTIVE ACKNOWLEDGES AND AGREES THAT THE EXECUTIVE HAS HAD AN OPPORTUNITY TO ASK QUESTIONS AND CONSULT WITH AN ATTORNEY OF THE EXECUTIVE’S CHOICE BEFORE SIGNING THIS AGREEMENT. THE EXECUTIVE FURTHER ACKNOWLEDGES THAT THE EXECUTIVE’S
SIGNATURE BELOW IS AN AGREEMENT TO RELEASE EMPLOYER AND EMPLOYER GROUP FROM ANY AND ALL CLAIMS THAT CAN BE RELEASED AS A MATTER OF LAW. 

[SIGNATURE PAGE FOLLOWS] 

  
 15 

 IN WITNESS WHEREOF, the Parties have executed this Agreement as of the Execution Date
above. 
  

			
	Castle Creek Biosciences, Inc.
		
	By:	 	     /s/ Matthew Gantz

	Name: Matthew Gantz
	Title: President and CEO

  

			
	EXECUTIVE
		
	Signature:	 	 /s/ John Maslowski

		 	John Maslowski

  
 16

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00330-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00330-of-00352.parquet"}]]